HK1038355A1 - Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer. - Google Patents
Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer.Info
- Publication number
- HK1038355A1 HK1038355A1 HK01109123A HK01109123A HK1038355A1 HK 1038355 A1 HK1038355 A1 HK 1038355A1 HK 01109123 A HK01109123 A HK 01109123A HK 01109123 A HK01109123 A HK 01109123A HK 1038355 A1 HK1038355 A1 HK 1038355A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combinations
- coa reductase
- reductase inhibitors
- treat cancer
- hmg coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8520298P | 1998-05-12 | 1998-05-12 | |
| US9225398P | 1998-07-10 | 1998-07-10 | |
| PCT/US1999/010188 WO1999058505A2 (en) | 1998-05-12 | 1999-05-10 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1038355A1 true HK1038355A1 (en) | 2002-03-15 |
Family
ID=26772425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK01109123A HK1038355A1 (en) | 1998-05-12 | 2001-12-27 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6492410B1 (xx) |
| EP (1) | EP1077949A2 (xx) |
| JP (1) | JP2002514628A (xx) |
| KR (1) | KR20010043529A (xx) |
| CN (1) | CN1171874C (xx) |
| AP (1) | AP2000001984A0 (xx) |
| AU (1) | AU758891B2 (xx) |
| BG (1) | BG105003A (xx) |
| BR (1) | BR9911785A (xx) |
| CA (1) | CA2331295A1 (xx) |
| EA (1) | EA003860B1 (xx) |
| EE (1) | EE200000660A (xx) |
| GE (1) | GEP20032996B (xx) |
| HK (1) | HK1038355A1 (xx) |
| HR (1) | HRP20000771A2 (xx) |
| HU (1) | HUP0102322A3 (xx) |
| ID (1) | ID27933A (xx) |
| IL (1) | IL139502A0 (xx) |
| IS (1) | IS5713A (xx) |
| NO (1) | NO20005680L (xx) |
| NZ (1) | NZ508357A (xx) |
| OA (1) | OA11551A (xx) |
| PL (1) | PL344662A1 (xx) |
| SK (1) | SK16742000A3 (xx) |
| WO (1) | WO1999058505A2 (xx) |
| YU (1) | YU68900A (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002536405A (ja) * | 1999-02-11 | 2002-10-29 | イーデンランド、インコーポレイテッド | ウイルス感染症の治療方法 |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| WO2005042710A1 (en) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| US8026377B2 (en) * | 2005-11-08 | 2011-09-27 | Ranbaxy Laboratories, Limited | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
| US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
| US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| WO1997000894A1 (en) * | 1995-06-22 | 1997-01-09 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| WO1997000895A1 (en) | 1995-06-22 | 1997-01-09 | Biogen, Inc. | Crystals of fragments of cd40 ligand and their use |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 EE EEP200000660A patent/EE200000660A/xx unknown
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
- 1999-05-10 EP EP99922898A patent/EP1077949A2/en not_active Withdrawn
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Application Discontinuation
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 CA CA002331295A patent/CA2331295A1/en not_active Abandoned
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/en not_active Application Discontinuation
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-13 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
-
2001
- 2001-12-27 HK HK01109123A patent/HK1038355A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999058505A2 (en) | 1999-11-18 |
| CA2331295A1 (en) | 1999-11-18 |
| BG105003A (en) | 2001-07-31 |
| BR9911785A (pt) | 2001-04-03 |
| WO1999058505A3 (en) | 2000-01-06 |
| NO20005680L (no) | 2001-01-10 |
| EP1077949A2 (en) | 2001-02-28 |
| JP2002514628A (ja) | 2002-05-21 |
| KR20010043529A (ko) | 2001-05-25 |
| HRP20000771A2 (en) | 2001-06-30 |
| EE200000660A (et) | 2002-04-15 |
| CN1171874C (zh) | 2004-10-20 |
| IL139502A0 (en) | 2001-11-25 |
| EA003860B1 (ru) | 2003-10-30 |
| HUP0102322A2 (hu) | 2001-11-28 |
| AP2000001984A0 (en) | 2000-12-31 |
| PL344662A1 (en) | 2001-11-19 |
| ID27933A (id) | 2001-05-03 |
| GEP20032996B (en) | 2003-06-25 |
| NZ508357A (en) | 2002-09-27 |
| HUP0102322A3 (en) | 2001-12-28 |
| IS5713A (is) | 2000-11-10 |
| AU3979299A (en) | 1999-11-29 |
| CN1306515A (zh) | 2001-08-01 |
| YU68900A (sh) | 2002-12-10 |
| EA200001164A1 (ru) | 2001-06-25 |
| NO20005680D0 (no) | 2000-11-10 |
| OA11551A (en) | 2004-05-24 |
| AU758891B2 (en) | 2003-04-03 |
| US6492410B1 (en) | 2002-12-10 |
| SK16742000A3 (sk) | 2001-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2212299A (en) | Compositions and methods for the treatment of tumor | |
| AU2001236519A1 (en) | Identification, assessment, prevention, and therapy of prostate cancer | |
| AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2495200A (en) | Compositions and methods for the treatment of tumor | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| HK1040490A1 (zh) | 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法 | |
| UA66793C2 (uk) | Лептин як стримувач швидкого збільшення пухлини клітини | |
| HK1038355A1 (en) | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer. | |
| PL352931A1 (en) | Compositions and uses of et743 for treating cancer | |
| AU2002367172A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU6435398A (en) | Prevention and treatment of hepatocellular cancer | |
| NO996206D0 (no) | Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer | |
| AU2002313426A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| AU3270301A (en) | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity | |
| DE50011084D1 (de) | Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs | |
| AU2001297571A1 (en) | Detection and treatment of prostate cancer | |
| PL337343A1 (en) | Method of obtaining drugs comprising inhibitors of hmg coa reductase | |
| AU1471300A (en) | Compositions and methods for treatment of cancer | |
| SI0986387T1 (en) | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| WO2004005463A9 (en) | Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer | |
| AUPO851597A0 (en) | Treatment of prostate cancer | |
| AU2224800A (en) | Compositions and methods for the treatment of tumor | |
| AU8719298A (en) | Treatment of prostate cancer | |
| AU1773601A (en) | Treatment or prevention of photoaging and skin cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20080510 |